- Kathleen Sebelius cites pharmacists' importance as Rite Aid CEO introduces Obamacare resource program
- On the heels of Q3, Walgreens outlines shift in front-end strategy and pharmacy tailwinds looking forward
- New Rite Aid group VP pharmacy initiatives and clinical services to oversee Wellness Ambassador program
- Senate passes Drug Quality and Security Act
- Facing pharmacy trends for the remainder of the year
SILVER SPRING, Md. — The Food and Drug Administration has approved a new use for a cancer drug made by Roche unit Genentech, the agency said.
The FDA announced the approval of Avastin (bevacizumab) combined with fluoropyrimidine-irinotecan or fluoropyrimidine-oxaliplatin chemotherapy for treating colorectal cancer that has spread to other parts of the body, also known as metastatic colorectal cancer, or mCRC.
The drug is also approved for treating lung cancer, kidney cancer and brain cancer.